SaverOne: How Much Time Yorkville Really Buys, And How Much Per-Share Value It Burns

The main article already argued that SaverOne's problem is no longer just commercialization pace, but how much value is left for common shareholders after the financing layer. This follow-up isolates the Yorkville line itself: how much time it really buys, and what per-share price is being paid to buy it.

The right way to read this line is not through a $50 million headline, but through two hard numbers. At year-end 2025 the company had NIS 14.144 million of cash. In that same year it used NIS 29.207 million in operating cash flow, plus NIS 469 thousand of lease principal, NIS 50 thousand of government-grant repayments, and NIS 7 thousand of CAPEX. In other words, the cash bridge here is all-in cash flexibility: how much cash remains after the period's real cash uses. On that basis, year-end 2025 covered less than six months of activity.

That is also how the post-balance-sheet Yorkville sale should be read. The company sold 17.5068 billion ordinary shares to Yorkville for $2.485 million, but $569 thousand of that amount was already used for a partial repayment of the promissory note. That is exactly why this continuation matters: not every dollar coming through Yorkville remains as operational oxygen.

How Much Time Yorkville Actually Buys

On the 2025 cash-use base, the NIS 14.144 million of cash at year-end equaled about 5.7 months of activity. The post-balance-sheet Yorkville sale adds about 3.2 more months on a gross basis. But after deducting the $569 thousand used to partially repay the promissory note, the true addition to cash runway falls to only about 2.5 months.

That is the core point. Even before asking how many shares were needed to obtain the cash, the line did not buy SaverOne a year of breathing room. It bought roughly a quarter. Economically, this is bridge financing, not a financing solution.

Another easy point to miss is that SEPA III did not start as a clean equity backstop even before the January-March 2026 sale. Yorkville advanced only $1.5 million upfront, not the full line size, and the company says that after the 3% discount and legal fees, net cash received was about $1.43 million. At the same time, the promissory note carries 8% interest and must be repaid in ten equal monthly installments beginning on January 28, 2026. So even before the business proved a broader commercial scale, the line already came with interest, amortization, and use pressure.

How Much Per-Share Value Gets Burned On The Way

The real cost of that oxygen is not only in the number of shares. It is also in the sharp collapse in how much cash each billion shares actually brings in.

Put more simply, during 2025 the company received about $880 thousand of gross proceeds for every billion shares sold through Yorkville. In the post-balance-sheet sale it received only about $142 thousand of gross proceeds per billion shares, and only about $109 thousand of net operational runway per billion shares after the note repayment. That is roughly an 84% collapse in gross proceeds per billion shares versus the 2025 average.

This is why dilution is no longer merely a side effect of financing. It has become the economics of the financing itself. The more the company needs to keep selling shares at weaker prices to buy more time, the more each additional million dollars erases per-share economics compared with just a few months earlier.

The picture becomes even sharper when the equity note is bridged to the market snapshot. At year-end 2025 the share count stood at 10.2559 billion. In the market snapshot dated April 3, 2026, the share count was already 27.7627 billion. The difference between those two figures, 17.5068 billion shares, exactly matches the post-balance-sheet Yorkville sale. In other words, the entire jump in the share count between year-end and the current market snapshot is explained by that Yorkville sale alone.

If the Yorkville-created shares from 2025 are included as well, the picture is even harsher: Yorkville facilities created about 27.15 billion shares from January 1, 2025 onward. Relative to the April 2026 market snapshot, that is about 97.8% of the current share base. This is not a minor capital-structure footnote. It is now the stock story.

Why The $50 Million Headline Is Not A Closed Funding Route

This is not a $50 million cash balance. SEPA III is a line of up to $50 million over 36 months, subject to conditions, restrictions, and draw notices. That is very different from cash already sitting on the balance sheet.

The document itself makes that clear. The company explicitly says that to use credit or equity facilities it must comply with regulatory requirements, including continued Nasdaq listing. At the same time, the 20-F risk disclosure says that if the ADS bid price falls below $1 again for another 30 consecutive trading days before October 2026, the company would be exposed to immediate Nasdaq delisting without a new cure period. That turns listing risk from a sentiment issue into a direct financing risk.

There are also built-in line restrictions. Yorkville is not required to purchase ADSs if the purchase would bring it above 9.99% beneficial ownership of the company's share capital or voting power. In addition, the company undertook to pay a $25 thousand structuring fee and a commitment fee equal to 1% of the line size, with the first $100 thousand due in ADSs within five days of signing SEPA III. So the line does not just buy time. It charges for opening the clock.

That is why the correct headline is not "the company has a $50 million line." The correct headline is the company has a conditional, rolling funding route that starts from a small advance, depends on staying listed on Nasdaq, and destroys more and more per-share economics as the share price weakens.

Bottom Line

Yorkville did not solve SaverOne's 2026 route. It merely bought more time, at a worsening price. On a 2025 cash-use basis, the post-balance-sheet sale bought only about 2.5 months of net operational runway. The cost was 17.5068 billion shares, which on their own explain the entire increase in the share count between year-end 2025 and the April 2026 market snapshot.

The reasonable counter-thesis is that if the ADS price stabilizes, if the company maintains Nasdaq, and if new revenue arrives from the current routes or the defense pivot, Yorkville could serve as a backstop rather than as an erasure mechanism. That remains possible. But on the evidence currently in the filings, Yorkville looks less like a growth enabler and more like a financing machine that buys quarters at an increasingly expensive price for existing shareholders.

So the key question for the next 2-4 quarters is not whether another draw notice exists on paper. The question is whether SaverOne can produce business proof that reduces dependence on buying time this way, before the next million dollars requires yet another even harder layer of shares.